New data on navenibart, a potential HAE medicine currently being trialled, to be presented at scientific conferences

Two abstracts on navenibart, which is currently undergoing testing amongst HAE patients, will be presented at the forthcoming 14^th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary, and the Eastern Allergy Conference (EAC) in Palm Beach, Florida. The abstract details, shared with HAEi, are:

• Navenibart for hereditary angioedema (HAE): Analysis of safety, pharmacokinetic, and pharmacodynamic data from Phase 1a and Phase 1b/2 ALPHA-STAR trial
• Treatment with navenibart (STAR-0215) reduces attack severity and use of rescue medication in patients with hereditary angioedema (HAE): Interim results from the ALPHA-STAR trial

Both meetings will take place from 29 May – 1 June 2025.

(Source: Astria)